Video Experimental Relacionado

Updated: Sep 10, 2025

Methods for Detecting Cough and Airway Inflammation in Mice

Methods for Detecting Cough and Airway Inflammation in Mice

Published on: August 2, 2024

Chemerin exacerba la inflamación pulmonar en la diabetes tipo 2 y la infección por Mycobacterium Tuberculosis

Giseli Furlan Corrêa¹, Núbia Sabrina Martins¹, Ualter Guilherme Cipriano¹

¹Basic and Applied Immunology Program, Ribeirao Preto Medical School, University of Sao Paulo, 3900 Bandeirantes Ave., Ribeirao Preto, SP, Brazil.

|August 21, 2025

Resumen

El bloqueo del receptor de la quimerina puede ayudar a tratar la tuberculosis en pacientes con diabetes tipo 2. Este enfoque podría reducir la inflamación pulmonar relacionada con esta enfermedad compleja.

Área de la Ciencia:

Inmunología
Endocrinología
Enfermedades infecciosas

Sus antecedentes:

La quimerina, una adipoquina, está elevada en la obesidad y la diabetes tipo 2.
La diabetes tipo 2 aumenta el riesgo, la gravedad y la resistencia al tratamiento de la tuberculosis (TB).
Los pacientes con tuberculosis diabética muestran una respuesta inmune deteriorada y una capacidad microbicida reducida.

Objetivo del estudio:

Investigar el efecto inflamatorio de la quimerina en los macrófagos.
Determinar el papel de la quimerina en los pulmones durante la infección por Mycobacterium tuberculosis en ratones con hiperglucemia.

Principales métodos:

Macrófagos derivados de la médula ósea tratados con un medio hiperglucémico y M. tuberculosis.
Se analizó la secreción de citoquinas inflamatorias (IL-6, IL-10) después del tratamiento con quimerina.
Se utilizaron ratones obesos (HFD) y diabéticos (db/db) infectados con M. tuberculosis
Se administró un antagonista de los receptores de quimerina (CCX832) a ratones infectados por db/db.

Principales resultados:

El tratamiento con quimerina aumentó la IL-6 y disminuyó la IL-10 en pacientes con DMBM hiperglucémica infectados con M. tuberculosis.
La DMBM de los obesos y no diabéticos fue proinflamatoria; la DMBM de los obesos y diabéticos no mostró diferencias con respecto a los controles.
In vivo, los ratones db/db tenían una mayor carga bacteriana y inflamación pulmonar.
El tratamiento con antagonistas redujo la inflamación pulmonar en ratones db/db sin afectar la carga bacteriana.

Conclusiones:

La señalización de la quimerina agrava la inflamación pulmonar en la diabetes tipo 2 durante la tuberculosis.
El bloqueo de los receptores de quimerina (ChemR23) puede mitigar la patología pulmonar asociada a la tuberculosis en individuos diabéticos.
Esto sugiere una terapia adyuvante potencial para el manejo de casos complejos de TB.

Palabras clave:

La quimioterapia Inflamación de los pulmones La tuberculosis Diabetes tipo 2

Más Videos Relacionados

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Published on: February 17, 2014

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

Videos de Conceptos Relacionados

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...